Name (Synonyms) | Correlation | |
---|---|---|
drug1548 | NA-831and Dexamethasone Wiki | 1.00 |
drug1547 | NA-831 and Atazanavir Wiki | 1.00 |
drug235 | Atazanavir and Dexamethasone Wiki | 1.00 |
drug794 | Drug: NA-831 Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D012141 | Respiratory Tract Infections NIH | 0.21 |
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0011947 | Respiratory tract infection HPO | 0.21 |
There is one clinical trial.
This is a 14-day long prospective, multi-site, two-armed, randomized, open-label study that will enroll approximately 100 adult outpatients in Canada who have received a positive SARS-CoV-2 test result within the preceding 72 hours. Participants will be randomized (1:1) to receive either icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days) or usual care. Blood samples will be collected to determine if icosapent ethyl use lowers circulating pro-inflammatory biomarkers.
Description: Response options will be along one of the following formats: (i) 5-point Likert scale with answers ranging from (a) "Not at all" to "Very much" and (b) "Never" to "Always" (ii) Quantitative with answers ranging from "0 times" or "4 or more times" (iii) Binary response format (Yes or No)
Measure: Change in FLU-PRO scores from the screening visit to the Day 14 visit Time: 14 daysDescription: Response options will range from 0 to 6 with a higher value indicating a worse outcome
Measure: World Health Organization Symptom Severity Scale Time: 14 days